# Xlife Sciences AG Investor Relations

> Xlife Sciences AG (SIX Swiss Exchange: XLS, ISIN: CH0461929603) is a Swiss
> incubator and accelerator that develops and commercialises early-stage life
> sciences research originating from universities and research institutions. The
> portfolio spans four segments — technology platforms, biotechnology and
> therapeutics, medical technology, and artificial intelligence / digital health.
> The company is headquartered in Zurich, Switzerland and publishes ad-hoc and
> regulatory disclosures in accordance with SIX Swiss Exchange listing rules. This
> file provides AI assistants with a curated entry point to Xlife Sciences' public
> investor disclosures. For real-time figures, always fetch the linked source page.

## About the company
- [Xlife Sciences at a glance](https://www.xlifesciences.ch/#ataglance): Founding year, headquarters, FTEs, and portfolio companies
- [Why invest](https://www.xlifesciences.ch/#why-invest): Reasons to invest in Xlife Sciences
- [Strategic pillars](https://www.xlifesciences.ch/#strategy): Early-stage focus, active management, diversified portfolio, ecosystem approach
- [Business segments](https://www.xlifesciences.ch/#business-areas): Technology platforms, biotechnology and therapeutics, medical technology, artificial intelligence
- [Mission and vision](https://www.xlifesciences.ch/#vision): Bridging research and healthcare markets
- [Business model](https://www.xlifesciences.ch/#business-model): How Xlife Sciences identifies, develops, and commercialises research projects
- [Investment process](https://www.xlifesciences.ch/#investment-process): From invention disclosure through scientific assessment to exit
- [Financial highlights](https://www.xlifesciences.ch/#financial-highlights): Key financial figures

## Portfolio segments
- [Technology platforms](https://www.xlifesciences.ch/technology-platforms): Cross-indication platform companies including VERAXA Biotech, palleos healthcare, Inflamed Pharma, Inventum Genetics
- [Biotechnology and therapeutics](https://www.xlifesciences.ch/biotechnologies-therapeutics): Novel treatment options across oncology, inflammation, regenerative medicine, and gene therapy
- [Medical technology](https://www.xlifesciences.ch/medical-technology): Diagnostics and patient monitoring innovations
- [Artificial intelligence](https://www.xlifesciences.ch/artificial-intelligence): AI and digital medicine applications

## Financial reports
- [Financial reports](https://www.xlifesciences.ch/financials#financial-reports): Annual and interim reports
- [Financial calendar](https://www.xlifesciences.ch/financials#calendar): Upcoming results and events
- [Analyst coverage](https://www.xlifesciences.ch/financials#analysts): Sell-side analysts covering Xlife Sciences
- [The share and financials](https://www.xlifesciences.ch/financials#the-share): Share information and capital data

## Governance
- [Management, team and Board of Directors](https://www.xlifesciences.ch/governance#management-and-board): Executive management and Board of Directors
- [Advisory Board](https://www.xlifesciences.ch/governance#Advisory-board): Scientific and strategic advisors
- [Governance documents](https://www.xlifesciences.ch/governance#documents): Resolutions and Articles of Association (Statutes)

## Sustainability
- [Sustainability at Xlife Sciences](https://www.xlifesciences.ch/esg#sustainability): ESG framework
- [Our ESG journey](https://www.xlifesciences.ch/esg#ESG-journey): ESG milestones and approach
- [Sustainability reports](https://www.xlifesciences.ch/esg#sustainability-reports): Published ESG reports
- [Code of Conduct](https://www.xlifesciences.ch/esg#code-of-conduct): Conduct standards

## News and disclosures
- [News and ad hoc announcements](https://www.xlifesciences.ch/media#news): Latest news and ad hoc disclosures
- [Press releases and ad hoc news archive](https://www.xlifesciences.ch/press-releases-and-ad-hoc-news): Full archive of press releases and ad hoc news
- [Investor presentation](https://www.xlifesciences.ch/media#investor-presentation): Latest investor presentation
- [Subscribe to updates](https://www.xlifesciences.ch/media#subscribe): Email subscription for press releases, ad hoc news, and newsletter

## Contact
- [Contact](https://www.xlifesciences.ch/contact-us): Investor and corporate enquiries